MarketPulse

IPF

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oorja Bio Raises $30M to Develop First-in-Class IPF Therapy ORJ-001

Oorja Bio launches with $30M Series A to develop ORJ-001, a first-in-class peptide therapy for idiopathic pulmonary fibrosis, with Phase 2 trials planned for 2026.
MRKGILDPhase 2 clinical trialSeries A funding
BenzingaBenzinga··Na

Rein Therapeutics Raises $57.5M to Advance Pulmonary Fibrosis Drug Trial

Rein Therapeutics closed a $57.5 million public offering to fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis, with runway extended through Q1 2028.
RNTXclinical trialpublic offering
BenzingaBenzinga··Na

Trevi Therapeutics Prices $150M Stock Offering as It Advances Chronic Cough Treatment

Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.
TRVIstock offeringclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Trevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough

Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.
TRVIclinical-stagepublic offering
BenzingaBenzinga··Vandana Singh

United Therapeutics Surges 16.5% on Positive Lung Disease Trial Results

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial